Abstract:Journal of Extracellular VesiclesVolume 6, Issue 1 1396823 Editorial of the ISEV boardOpen Access Updating the MISEV minimal requirements for extracellular vesicle studies: building bridges to reproducibility Kenneth W. Witwer, Kenneth W. Witwer kwitwer1@jhmi.edu orcid.org/0000-0003-1664-4233 Departments of Molecular and Comparative Pathobiology and Neurology, The Johns Hopkins University School of Medicine, Baltimore, USASearch for more papers by this authorCarolina Soekmadji, Carolina Soekmadji orcid.org/0000-0002-6920-6627 Department of Cell and Molecular Biology, QIMR Berghofer Medical Research Institute, Brisbane, AustraliaSearch for more papers by this authorAndrew F. Hill, Andrew F. Hill orcid.org/0000-0001-5581-2354 Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, AustraliaSearch for more papers by this authorMarca H. Wauben, Marca H. Wauben Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The NetherlandsSearch for more papers by this authorEdit I. Buzás, Edit I. Buzás Department of Genetics, Cell- and Immunobiology, Semmelweis University and MTA-SE Immunoproteogenomics Extracellular Vesicle Research Group, Budapest, HungarySearch for more papers by this authorDolores Di Vizio, Dolores Di Vizio Division of Cancer Biology and Therapeutics, Departments of Surgery, Biomedical Sciences, and Pathology and Laboratory Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USASearch for more papers by this authorJuan M. Falcon-Perez, Juan M. Falcon-Perez Exosomes Laboratory & Metabolomics Platform, CIC bioGUNE, CIBERehd, Derio, Spain IKERBASQUE Research Science Foundation, Bilbao, SpainSearch for more papers by this authorChris Gardiner, Chris Gardiner Research Department of Haematology, University College London, London, UKSearch for more papers by this authorFred Hochberg, Fred Hochberg Neurosurgery, University of California at San Diego, San Diego, CA, USA The Scintillon Institute, La Jolla, CA, USASearch for more papers by this authorIgor V. Kurochkin, Igor V. Kurochkin Central Research Laboratories, Sysmex Co, Kobe, JapanSearch for more papers by this authorJan Lötvall, Jan Lötvall orcid.org/0000-0001-9195-9249 Codiak BioSciences, Cambridge, MA, USA Krefting Research Centre, University of Gothenburg, Gothenburg, SwedenSearch for more papers by this authorSuresh Mathivanan, Suresh Mathivanan Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, AustraliaSearch for more papers by this authorRienk Nieuwland, Rienk Nieuwland Department of Clinical Chemistry and Vesicle Observation Centre, Academic Medical Centre of the University of Amsterdam, Amsterdam, The NetherlandsSearch for more papers by this authorSusmita Sahoo, Susmita Sahoo Department of Medicine, Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY, USASearch for more papers by this authorHidetoshi Tahara, Hidetoshi Tahara Department of Cellular and Molecular Biology, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, JapanSearch for more papers by this authorAna Claudia Torrecilhas, Ana Claudia Torrecilhas Departamento de Ciências Farmacêuticas, UNIFESP, Diadema, BrazilSearch for more papers by this authorAlissa M. Weaver, Alissa M. Weaver orcid.org/0000-0002-4096-8636 Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN, USASearch for more papers by this authorHang Yin, Hang Yin Center of Basic Molecular Science, Department of Chemistry, Tsinghua University, Beijing, China Department of Chemistry and Biochemistry and the BioFrontiers Institute, University of Colorado Boulder, Boulder, CO, USASearch for more papers by this authorLei Zheng, Lei Zheng Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of ChinaSearch for more papers by this authorYong Song Gho, Yong Song Gho Department of Life Sciences, POSTECH (Pohang University of Science and Technology), Pohang, South KoreaSearch for more papers by this authorPeter Quesenberry, Peter Quesenberry Brown Medical School, Rhode Island Hospital, Providence, RI, USASearch for more papers by this authorClotilde Théry, Clotilde Théry clotilde.thery@curie.fr Institut Curie, INSERM U932, PSL Research University, Paris, FranceSearch for more papers by this author Kenneth W. Witwer, Kenneth W. Witwer kwitwer1@jhmi.edu orcid.org/0000-0003-1664-4233 Departments of Molecular and Comparative Pathobiology and Neurology, The Johns Hopkins University School of Medicine, Baltimore, USASearch for more papers by this authorCarolina Soekmadji, Carolina Soekmadji orcid.org/0000-0002-6920-6627 Department of Cell and Molecular Biology, QIMR Berghofer Medical Research Institute, Brisbane, AustraliaSearch for more papers by this authorAndrew F. Hill, Andrew F. Hill orcid.org/0000-0001-5581-2354 Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, AustraliaSearch for more papers by this authorMarca H. Wauben, Marca H. Wauben Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The NetherlandsSearch for more papers by this authorEdit I. Buzás, Edit I. Buzás Department of Genetics, Cell- and Immunobiology, Semmelweis University and MTA-SE Immunoproteogenomics Extracellular Vesicle Research Group, Budapest, HungarySearch for more papers by this authorDolores Di Vizio, Dolores Di Vizio Division of Cancer Biology and Therapeutics, Departments of Surgery, Biomedical Sciences, and Pathology and Laboratory Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USASearch for more papers by this authorJuan M. Falcon-Perez, Juan M. Falcon-Perez Exosomes Laboratory & Metabolomics Platform, CIC bioGUNE, CIBERehd, Derio, Spain IKERBASQUE Research Science Foundation, Bilbao, SpainSearch for more papers by this authorChris Gardiner, Chris Gardiner Research Department of Haematology, University College London, London, UKSearch for more papers by this authorFred Hochberg, Fred Hochberg Neurosurgery, University of California at San Diego, San Diego, CA, USA The Scintillon Institute, La Jolla, CA, USASearch for more papers by this authorIgor V. Kurochkin, Igor V. Kurochkin Central Research Laboratories, Sysmex Co, Kobe, JapanSearch for more papers by this authorJan Lötvall, Jan Lötvall orcid.org/0000-0001-9195-9249 Codiak BioSciences, Cambridge, MA, USA Krefting Research Centre, University of Gothenburg, Gothenburg, SwedenSearch for more papers by this authorSuresh Mathivanan, Suresh Mathivanan Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, AustraliaSearch for more papers by this authorRienk Nieuwland, Rienk Nieuwland Department of Clinical Chemistry and Vesicle Observation Centre, Academic Medical Centre of the University of Amsterdam, Amsterdam, The NetherlandsSearch for more papers by this authorSusmita Sahoo, Susmita Sahoo Department of Medicine, Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY, USASearch for more papers by this authorHidetoshi Tahara, Hidetoshi Tahara Department of Cellular and Molecular Biology, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, JapanSearch for more papers by this authorAna Claudia Torrecilhas, Ana Claudia Torrecilhas Departamento de Ciências Farmacêuticas, UNIFESP, Diadema, BrazilSearch for more papers by this authorAlissa M. Weaver, Alissa M. Weaver orcid.org/0000-0002-4096-8636 Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN, USASearch for more papers by this authorHang Yin, Hang Yin Center of Basic Molecular Science, Department of Chemistry, Tsinghua University, Beijing, China Department of Chemistry and Biochemistry and the BioFrontiers Institute, University of Colorado Boulder, Boulder, CO, USASearch for more papers by this authorLei Zheng, Lei Zheng Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of ChinaSearch for more papers by this authorYong Song Gho, Yong Song Gho Department of Life Sciences, POSTECH (Pohang University of Science and Technology), Pohang, South KoreaSearch for more papers by this authorPeter Quesenberry, Peter Quesenberry Brown Medical School, Rhode Island Hospital, Providence, RI, USASearch for more papers by this authorClotilde Théry, Clotilde Théry clotilde.thery@curie.fr Institut Curie, INSERM U932, PSL Research University, Paris, FranceSearch for more papers by this author First published: 01 December 2017 https://doi.org/10.1080/20013078.2017.1396823Citations: 110AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat An editorial describing "minimal experimental requirements for definition of extracellular vesicles (EVs)", or more simply "minimal information for studies of EVs (MISEV)" was published in the Journal of Extracellular Vesicles in late 2014 [1]. Similar to guidelines in other scientific fields [2-4], "MISEV2014", as we will call it here, provided recommendations on experimental methods and minimal information in reporting. Specifically, three key areas were addressed: EV isolation/purification, EV characterization and EV functional studies (see Text Box 1). Table Text Box 1. Major recommendations of MISEV2014. 1. EV separation/isolation a) There is no single optimal isolation method, so choose based on the downstream applications and scientific question b) Report all details of the method(s) for reproducibility 2. EV characterization a) General characterization. Show: i. At least three positive protein markers of EVs, including at least one -transmembrane/lipid-bound protein -cytosolic protein ii. At least one negative protein marker b) Characterization of single vesicles: use two different but complementary techniques, for example: i. electron or atomic force microscopy (and show both close-up and wide-field) ii. single particle tracking 3. Functional studies should include: a) Dose–response studies b) Process controls to rule out influence of serum components/other possible contaminants c-i.) Density gradients to show activity is intrinsic to EVs, not just associated or c-ii.) EV depletion to remove activity or c-iii.) EV/cell labelling (e.g., fluorescent labelling, with careful interpretation) Brief review of MISEV2014 On separation of EVs (also referred to as isolation, purification or concentration), MISEV2014 acknowledged that there is no consensus on an "optimal" method, such as ultracentrifugation, size exclusion or immunoaffinity. Instead, selection of a method should be guided by the relevant scientific question and downstream applications, and all details of the method should be provided to ensure reproducibility. MISEV2014 recommended that EVcharacterization be performed at both the population and single vesicle levels. For the former, both positive and negative protein marker characterization was endorsed, following four categories of proteins: (1) transmembrane or lipid-bound EV protein, (2) EV cytosolic protein, (3) intracellular but not associated with plasma membrane or endosomes (i.e. relatively less abundant in exosomal EVs than in cells) and (4) extracellular but not typically EV-associated proteins. Several examples of proteins in each category were provided. For characterization of single vesicles, as a means to assess population heterogeneity, MISEV2014 called for the use of at least two different but complementary technologies. For example, electron or atomic force microscopy could be paired with one of the single particle tracking methods. Furthermore, close-up images should be accompanied by wide-field views to allow assessment of heterogeneity. For EV functional studies, MISEV2014 stated that quantitation of EVs and their activity should include dose–response studies. Process controls should be included, since contaminants might contribute activity. Use of density gradients was encouraged to show that any observed activity is intrinsic to EVs and not to closely associated, commonly co-purifying particles; alternatively, this activity should be depletable, e.g. by immunodepletion of EVs. Labelling studies were also recommended. Rigour vs flexibility MISEV2014 reflected a field in flux, with a need for standard development tempered by remaining uncertainties. Indeed, this is still the case. For this reason, the protein markers for general characterization that were listed in a table in the manuscript were presented as non-exclusive examples only, and no specific antibodies were recommended. Our understanding of categories such as "EV proteins" and "non-EV proteins" is still evolving, and these categories might better be labelled "EV-enriched" and "EV-depleted". Some described non-EV proteins have been found in vesicles and have biological effects. Instead of an inflexible approach, MISEV2014 urged that markers from different categories be used, and that all antibody details and sample manipulations be reported to ensure interpretability and reproducibility. What if scientists could not follow all guidelines? In this case, they were encouraged to explain why certain experiments could not be performed. The example of low-abundance, precious samples was given explicitly. That is, guidance was accompanied by acknowledgement of the realities of the field. Utility of MISEV2014 The value of MISEV2014 is supported by a key finding of van Deun and Hendrix [5] reporting on the release of the EV-TRACK knowledgebase [6]. The EV-TRACK project includes an "EV-METRIC" that can be calculated to gauge the quality of reporting of each EV-related paper. van Deun et al. found that, in the year after the release of MISEV2014, the EV-METRICs of publications overall did not improve significantly. However, publications that cited MISEV2014 had significantly higher EV-METRICs. Those who engaged with MISEV2014, then, seemed to be better equipped to report important experimental parameters. Of course, it takes time for laboratories to incorporate new methodologies and then go on to publish a paper based on them. Laboratories that were unaware of the MISEV effort before its publication may simply not have had time to incorporate the guidelines by the time our survey took place. How far has MISEV reached? Citations of MISEV2014 reached 400 in September 2017, according to Google Scholar. However, this number represents only a minority of EV-related publications. While MISEV is likely followed in many publications that do not cite it, and citations per se are certainly not the goal of standardization efforts, the MISEV2014 citation rate nonetheless suggests that broader dissemination and researcher involvement could be achieved. Opportunities and pulse-checking The ISEV community now faces choices to extend the value and reach of MISEV2014. Whereas MISEV2014 was produced by the ISEV Board of Directors as the elected representatives of ISEV – at that time including the three editors-in-chief of the Journal of Extracellular Vesicles – future developments will benefit from the input of a much broader authorship. Drawing on more expertise will allow a future iteration or offshoot of MISEV2014 to offer more detailed guidance in more areas, and/or to reflect greater consensus. A first step in this direction was to take the pulse of the community on where we came from (MISEV2014) and where we are going with standardization. 2016 MISEV survey: obtaining guidance from the experts A 14-question MISEV survey was released to the ISEV membership on 24 October 2016. See Text Box 2 for an outline of the survey. A total of 187 responses were submitted: 81% (152) within a 24-hour period, and almost 95% within 5 days. The survey was closed in early 2017. Table Text Box 2. ISEV 2016 MISEV survey. 1. I have read the MISEV minimal requirements paper (Lötvall et al., JEV, 2014) (yes/no) 2. I have published on extracellular vesicles in 2015 and/or 2016 (yes/no) 3. In your recent EV publication(s), did you (follow/cite/not follow or cite) MISEV? 4. Do you think that minimal reporting and/or methodologic requirements are important for the EV field? (yes/no) 5. Which of the following most closely summarizes your opinion on minimal requirements in the EV field? ° Minimal requirements are important, and I support MISEV ° Minimal requirements are important, and MISEV does not go far enough to uphold standards ° Minimal requirements are important, but MISEV is too restrictive ° Minimal requirements such as MISEV are an unnecessary imposition on the EV field ° I don't have strong feelings about minimal requirements 6. If standards are to be adopted, which of the following is preferable? ° ISEV, with a large and diverse membership, should continue to take the lead in establishing minimal requirements ° Minimal requirements are better established by national societies or regional collaborative networks ° Leading experts or laboratories should develop and publish their own standards, and the best (highest IF or most cited) publications will eventually become the de facto standards in the field ° I have no preference 7. An update to MISEV is planned … how should it proceed? ° The ISEV board and JEV editors should update MISEV as they see fit. ° The ISEV board should also recruit ISEV members who are not on the board to assist in updating MISEV ° The ISEV community as a whole should be involved in updating MISEV, with invitations to contribute to specific points; community-wide voting is not needed ° The ISEV community should be involved not only in contributing/feedback, but also in voting to ratify specific points 8. Please comment on sections/types of information should be retained in future MISEV updates (check all that are applicable) ° minimal requirements to claim the presence of EVs in isolates ° general characterization of EVs ° characterization of single EVs ° studies of functional activities of EVs ° recommendations for controls ° other/comments on the above 9. Needed additions to MISEV include: ° Advice on pros and cons of different isolation methods ° Advice on protein markers to use for different types of EVs ° Advice on reliable antibodies for the EV protein markers, for different applications (WB, flow cytometry, immunohistochemistry, EM, etc.) ° Other (please specify) 10. If you would like to be involved in drafting or reviewing an update to MISEV, please provide your email address. Note: There will be additional opportunities to join the effort if you prefer not to disclose here. (Free form, optional) 11. If you would like to be involved in drafting or reviewing an update to MISEV, please describe your expertise in the EV field (e.g., published articles, unpublished work, specific areas of interest) (short answer, optional) 12. The following ISEV members should be consulted on MISEV updates (free form, optional) 13. If required, I/my laboratory are likely willing and able to devote a reasonable amount of resources to evaluate specific methods/reagents in the laboratory as needed to support a new MISEV release or other field-wide evaluation (yes/no) 14. Please share any other comments you may have (free form, optional) Respondents and their engagement with the MISEV2014 guidelines (Questions 1–3) Eighty-two per cent of respondents had read the MISEV2014 guidelines, whereas 18% had not. Fifty-six per cent of all respondents had published on EVs in 2015 or 2016 (i.e. after MISEV2014 appeared), whereas 44% had not. A slightly larger percentage of recent authors had read MISEV2014 (87%) compared with those who had not published on EVs recently (74%, Figure 1(a)). Seventy-one per cent of recently publishing authors indicated that they followed and/or cited MISEV2014 in their work (Figure 1(b)). Figure 1Open in figure viewerPowerPoint Community engagement with MISEV. Perceived importance of guidelines (Questions 4 and 5) Since the MISEV2014 authors have received a wide range of praise and critical comments on the guidelines, we sought to determine how the ISEV community viewed EV reporting or experimental guidelines in general and MISEV2014 specifically. When the question was phrased, "Do you think that minimal reporting and/or methodologic requirements are important for the EV field?" (Question 4), only one respondent answered "no" (Figure 2(a)). There was thus near-unanimity among respondents that requirements are needed. A diversity of underlying opinions became apparent, though, through Question 5, a multiple-choice question about MISEV2014 in particular. Almost all respondents saw requirements as "important", and a majority (53%) supported MISEV2014 as is. However, 25% considered MISEV2014 to be too restrictive, whereas 16% said it was not stringent enough (Figure 2(b)). Four per cent thought that MISEV2014 was an unnecessary imposition on the field. In conclusion, most survey participants are in favour of standards, with a majority of respondents supporting MISEV2014. It is clear, though, that sizeable portions of the ISEV constituency might favour updates and changes to MISEV2014. Figure 2Open in figure viewerPowerPoint Opinions about minimal requirements in the EV field. Who should update MISEV2014 (Questions 6 and 7)? As for ISEV's role in updates to MISEV2014, approximately 80% of respondents named ISEV, "with its large and diverse membership", as the ideal body to issue requirements (Figure 3(a)). Other responses included "no preference" and nods to local or regional societies. Around 10% of respondents suggested that individual laboratories or scientists should publish requirements and that those with the highest impact factors or citations would become the de facto standards. The overwhelming emphasis on ISEV, however, places a responsibility on the society – leadership and membership – to advance standardization efforts for the field. One unambiguous outcome of the survey was that ISEV board members and JEV editors are not encouraged to update MISEV2014 alone. This approach was endorsed by only 4% of respondents (Figure 3(b)). Thirty-five per cent of participants asked the ISEV board to include ISEV members who are not on the board, and 62% felt that the entire ISEV community should be invited to participate. Of the latter group, approximately three in four said that community voting would not be necessary, whereas one in four favoured community-wide voting on specific points. Figure 3Open in figure viewerPowerPoint Who should establish and update minimal requirements? Assembling a team for ongoingstandardization efforts A key goal of the MISEV2014 survey was to begin the process of identifying EV experts in addition to the previous MISEV2014 authorship and the ISEV Board of Directors who are able and willing to contribute to future community efforts. Sixty-eight respondents volunteered by providing their email addresses. Only two of these respondents were MISEV2014 authors or members of the ISEV Board of Directors. Fifty-six of the volunteers gave details of their areas of expertise, including publications in many cases. Additionally, 20 respondents suggested other EV experts who, in their view, should be involved in future updates to MISEV. These names included 22 who were not authors of the previous MISEV2014 publication and are not on the current ISEV board. Only minimal overlap between the "volunteers" and "volunteered" was observed. Thus, in total, approximately 85 unique individuals were identified as possible contributors. As stated in the survey, additional calls for volunteers will be made in the future. What topics should be retained or added (Questions 8 and 9)? The majority of respondents were in favour of keeping all current components of MISEV2014, with 85% or more supporting retention of minimal requirements to claim presence of EVs in isolates, general characterization of EVs and suggestions for controls. Smaller majorities endorsed retention of single EV guidelines and recommendations for functional studies (Figure 4(a)). What should or could be added in future MISEV updates? For Question 9, three choices were provided (specific recommendations on isolation methods, specific antibodies for detection and markers of multiple subtypes), along with an "other" comments box. While the way in which the survey was constructed prevented selection of more than one choice, the responses including the free-form comments made it clear that all selections were popular (Figure 4(b)). Updated recommendations on isolation methods were requested, including assessment of the proliferating commercial kit-based options to isolate EVs. Recommendations for judging the purity of vesicles were emphasized: while the presence of EVs is often shown, the presence and percentage of contaminants continue to be often ignored. Respondents suggested that contaminants could be categorized further based on EV sources (biofluids, tissues, cell-culture conditioned medium). Some felt that lists of reliable antibodies to detect EV positive or negative protein markers would be helpful, as well as guidelines on RNA, lipids and other EV components. Further guidelines on isolation method for functional studies were also raised, since isolation methods with different resultant purities may alter the functional roles of EV in vivo. Issuing from this problem, recommendations on experimental measurement of the activity of impurities were deemed important to place the functional roles of EVs in proper context. Figure 4Open in figure viewerPowerPoint MISEV: suggested retentions and additions. Positive and negative markers and contamination Examining the free-form comments for Questions 8 and 9, multiple responses addressed the problem of contamination and positive and negative markers. How does one recognize and quantitate the various possible contaminants? Can we arrive at a consensus purity measurement? How can activity of non-EV components be excluded in functional studies? What is a negative marker? Is it found exclusively in non-EV contaminants, or can it also be present, if at reduced relative amounts, in EVs? Should positive EV markers merely be found in EVs, or must they also be enriched? Other suggestions for additions Several commenters stressed the need to accommodate studies of EVs from rare cell types, low-abundance body fluids and other exceptions, and not simply take a "one-size-fits-all" approach. Recommendations on different subtypes of EVs were an item of interest for several respondents, as were newer or newly applied methods for EV separation. Other comments suggested topics such as storage of EVs, assessment of stability and omics analysis specific to EVs. Final comments box A final comments box in the survey was used by <7% of respondents. Most of these free-form responses were positive general comments on MISEV. One comment suggested that, for a MISEV update, a comprehensive review of methodologies might be useful. Several commenters emphasized that any future MISEV release should continue to allow for exceptions: cases where the requirements might be waived or recognized as inapplicable. Further action from the community to spread the word about EV minimal standards to journals and journal editors was also encouraged. Where do we go from here? Building bridges to enhance reproducibility in research Revealing and centralizing methodologic details are part of successful standardization. To this end, we recognize with enthusiasm the EV-TRACK knowledgebase that was announced in Nature Methods [6] and in the accompanying letter to the editor [5]. We strongly encourage EV researchers to join the EV-TRACK initiative (www.evtrack.org), to use its tools to help guide effective research design and evaluation, and to obtain an EV-METRIC for each manuscript. We also hope the EV-METRIC will be included in submissions to the Journal of Extracellular Vesicles and to other journals, as well. How will MISEV be updated? In addition to exciting initiatives like EV-TRACK, minimal requirements in the field must also be updated regularly. This will be a large task as the field grows, and input is sought from a wider swath. We were interested to read a "guidelines to guidelines" recently published by Daniel J. Klionsky [7], noted autophagy researcher and the driving force behind the well-known autophagy guidelines. These guidelines, published in 2008 [8] and updated in 2012 [9] and 2016 [10], now include several thousand authors who reviewed the text and offered changes in a carefully guided manner. Klionsky's staged writing process and a distributed author invitation plan ensure efficient progress but broad embrace of the global research body. In our view, the type of community consensus and buy-in fostered by this approach is exactly what we feel would be most valuable to EV researchers in an upcoming manifestation of the MISEV guidelines and also consistent with what the MISEV survey respondents indicated about their willingness and desire to be involved. Regarding uncertainty Standardization through MISEV updates is important, but of course uncertainty will remain that cannot be removed through minimal requirements alone. On many specific questions in EV research, including, for example, some quite basic matters of pre-analytical variables, the jury is still out. Careful comparisons to resolve these questions are conducted and published less often than might be optimal. This is because of the resources they require, resources that could otherwise be channelled into evaluating biological hypotheses that are more likely to secure funding. Importantly – and perhaps surprisingly to those who are less familiar with our highly collaborative field – 55% of respondents to the MISEV survey said that they or their laboratories could "devote reasonable resources" to evaluations, if these were to become necessary for MISEV updates. The language was kept intentionally vague, but "evaluations" could mean anything from literature reviews to technical/experimental comparisons. It is encouraging that such a large percentage of participants indicated a willingness to engage in coordinated activities. As needed, a Standardization Committee of ISEV could be formed to establish working groups on topics that have not been fully addressed and thus focus the substantial energies of the community. Summary Overall, the response to the ISEV survey on MISEV2014 produced three core findings: the value of MISEV2014, the need for regular updates that involve the wider community and the strong commitment of the ISEV community to advance the field through standardization efforts. Acknowledgements The contributions of all respondents to the MISEV2014 survey are gratefully acknowledged. The drafting authors would like to mention funding sources: US NIH DA040385 (KWW and CT), US NIH AG057430 (KWW) and US DoD W81XWH-16-1-0736 (CS). Disclosure statement No potential conflict of interest was reported by the authors. Biography KWW, CT, AF and MHM prepared the survey. KWW and CS analysed the results and wrote the manuscript. CT provided writing and planning assistance. All authors read and approved the final manuscript and provided feedback. References 1Lotvall J, Hill AF, Hochberg F, et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J Extracell Vesicles [Internet]. 2014; 3: 1. Available from http://www.ncbi.nlm.nih.gov/pubmed/25536934 2Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem [Internet]. 2009 Feb 28; 55(4): 611– 8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19246619 3Brazma A, Hingamp P, Quackenbush J, et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet [Internet]. 2001 Dec 01; 29(4): 365– 371. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11726920 4Lee JA, Spidlen J, Boyce K, et al. MIFlowCyt: the minimum information about a flow cytometry experiment. Cytom Part A [Internet]. 2008 Oct; 73A(10): 926– 930. [cited 2017 Sep 16]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18752282 5van Deun J, Hendrix A. Is your article EV-TRACKed? J Extracell Vesicles. Forthcoming 2017; 1. 6van Deun J, Mestdagh P, Agostinis P, et al. EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research. Nat Methods [Internet]. 2017 Feb 28; 14(3): 228– 232. [cited 2017 Mar 1]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28245209 7Klionsky DJ. Developing a set of guidelines for your research field: a practical approach. Mol Biol Cell [Internet]. 2016 Mar 1; 27(5): 733– 738. [cited 2017 Sep 16]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26915690 8Klionsky DJ, Abeliovich H, Agostinis P, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy [Internet]. 2008 Feb; 4(2): 151– 175. [cited 2017 Sep 16]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18188003 9Klionsky D, Agholme L, Agnello M, et al. Guidelines for the use and interpretation of assays for monitoring autophagy Autophagy. 2012; 8(4): 445– 544. 10Klionsky DJ, Abdelmohsen K, Abe A, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). doi.org [Internet]. 2016 Jan 2. p. 1– 222. (1). [cited 2017 Sep 21]. Available form: https://www.ncbi.nlm.nih.gov/pubmed/26799652 Citing Literature Volume6, Issue1December 20171396823 FiguresReferencesRelatedInformation

Abstract:Cancer CommunicationsEarly View LETTER TO THE EDITOROpen Access Transcriptome-wide association analysis identified candidate susceptibility genes for nasopharyngeal carcinoma Yong-Qiao He, Yong-Qiao He State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorWen-Qiong Xue, Wen-Qiong Xue State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorDan-Hua Li, Dan-Hua Li State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorTong-Min Wang, Tong-Min Wang State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorZhi-Ming Mai, Zhi-Ming Mai School of Public Health, The University of Hong Kong, Hong Kong S.A.R., 999077 P. R. China Center for Nasopharyngeal Carcinoma Research, Research Grants Council Area of Excellence Scheme, The University of Hong Kong, Hong Kong S.A.R., 999077 P. R. China Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892 USASearch for more papers by this authorDa-Wei Yang, Da-Wei Yang School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, 510080 P. R. ChinaSearch for more papers by this authorChang-Mi Deng, Chang-Mi Deng State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorYing Liao, Ying Liao State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorWen-Li Zhang, Wen-Li Zhang State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorRuo-Wen Xiao, Ruo-Wen Xiao State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorLuting Luo, Luting Luo School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, 510080 P. R. ChinaSearch for more papers by this authorHua Diao, Hua Diao School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, 510080 P. R. ChinaSearch for more papers by this authorXiating Tong, Xiating Tong School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, 510080 P. R. ChinaSearch for more papers by this authorYanxia Wu, Yanxia Wu State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorJiang-Bo Zhang, Jiang-Bo Zhang State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorTing Zhou, Ting Zhou orcid.org/0000-0003-4349-2036 State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorXi-Zhao Li, Xi-Zhao Li State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorPei-Fen Zhang, Pei-Fen Zhang State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorXiao-Hui Zheng, Xiao-Hui Zheng State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorShao-Dan Zhang, Shao-Dan Zhang State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorYe-Zhu Hu, Ye-Zhu Hu State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorMinzhong Tang, Minzhong Tang Wuzhou Red Cross Hospital, Wuzhou, Guangxi, 543002 P. R. China Wuzhou Cancer Center, Wuzhou, Guangxi, 543002 P. R. ChinaSearch for more papers by this authorYuming Zheng, Yuming Zheng Wuzhou Red Cross Hospital, Wuzhou, Guangxi, 543002 P. R. China Wuzhou Cancer Center, Wuzhou, Guangxi, 543002 P. R. ChinaSearch for more papers by this authorYonglin Cai, Yonglin Cai Wuzhou Red Cross Hospital, Wuzhou, Guangxi, 543002 P. R. China Wuzhou Cancer Center, Wuzhou, Guangxi, 543002 P. R. ChinaSearch for more papers by this authorEllen T. Chang, Ellen T. Chang Center for Health Sciences, Exponent, Inc., Menlo Park, CA, 94025, Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, 94143 USASearch for more papers by this authorZhe Zhang, Zhe Zhang Department of Otolaryngology-Head and Neck Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021 P. R. ChinaSearch for more papers by this authorGuangwu Huang, Guangwu Huang Department of Otolaryngology-Head and Neck Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021 P. R. ChinaSearch for more papers by this authorSu-Mei Cao, Su-Mei Cao State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorQing Liu, Qing Liu State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorLin Feng, Lin Feng State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorYing Sun, Ying Sun orcid.org/0000-0002-5888-2929 Department of Radiation Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorMaria Li Lung, Maria Li Lung Center for Nasopharyngeal Carcinoma Research, Research Grants Council Area of Excellence Scheme, The University of Hong Kong, Hong Kong S.A.R., 999077 P. R. China Department of Clinical Oncology, The University of Hong Kong, Hong Kong S.A.R., 999077 P. R. ChinaSearch for more papers by this authorHans-Olov Adami, Hans-Olov Adami Clinical Effectiveness Group, Institute of Health and Society, University of Oslo, Oslo, 0316 Norway Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, 17177 SwedenSearch for more papers by this authorWeimin Ye, Weimin Ye Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, 17177 Sweden Department of Epidemiology and Health Statistics & Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, Fujian, 350122 P. R. ChinaSearch for more papers by this authorTai-Hing Lam, Tai-Hing Lam School of Public Health, The University of Hong Kong, Hong Kong S.A.R., 999077 P. R. China Center for Nasopharyngeal Carcinoma Research, Research Grants Council Area of Excellence Scheme, The University of Hong Kong, Hong Kong S.A.R., 999077 P. R. ChinaSearch for more papers by this authorWei-Hua Jia, Corresponding Author Wei-Hua Jia jiawh@sysucc.org.cn orcid.org/0000-0002-0528-8715 State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. China School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, 510080 P. R. China Correspondence Wei-Hua Jia, M.D., Ph.D. Professor, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dong Feng East Road, Guangzhou 510060, Guangdong, P. R. China. Email: jiawh@sysucc.org.cnSearch for more papers by this author Yong-Qiao He, Yong-Qiao He State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorWen-Qiong Xue, Wen-Qiong Xue State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorDan-Hua Li, Dan-Hua Li State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorTong-Min Wang, Tong-Min Wang State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorZhi-Ming Mai, Zhi-Ming Mai School of Public Health, The University of Hong Kong, Hong Kong S.A.R., 999077 P. R. China Center for Nasopharyngeal Carcinoma Research, Research Grants Council Area of Excellence Scheme, The University of Hong Kong, Hong Kong S.A.R., 999077 P. R. China Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892 USASearch for more papers by this authorDa-Wei Yang, Da-Wei Yang School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, 510080 P. R. ChinaSearch for more papers by this authorChang-Mi Deng, Chang-Mi Deng State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorYing Liao, Ying Liao State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorWen-Li Zhang, Wen-Li Zhang State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorRuo-Wen Xiao, Ruo-Wen Xiao State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorLuting Luo, Luting Luo School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, 510080 P. R. ChinaSearch for more papers by this authorHua Diao, Hua Diao School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, 510080 P. R. ChinaSearch for more papers by this authorXiating Tong, Xiating Tong School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, 510080 P. R. ChinaSearch for more papers by this authorYanxia Wu, Yanxia Wu State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorJiang-Bo Zhang, Jiang-Bo Zhang State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorTing Zhou, Ting Zhou orcid.org/0000-0003-4349-2036 State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorXi-Zhao Li, Xi-Zhao Li State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorPei-Fen Zhang, Pei-Fen Zhang State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorXiao-Hui Zheng, Xiao-Hui Zheng State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorShao-Dan Zhang, Shao-Dan Zhang State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorYe-Zhu Hu, Ye-Zhu Hu State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorMinzhong Tang, Minzhong Tang Wuzhou Red Cross Hospital, Wuzhou, Guangxi, 543002 P. R. China Wuzhou Cancer Center, Wuzhou, Guangxi, 543002 P. R. ChinaSearch for more papers by this authorYuming Zheng, Yuming Zheng Wuzhou Red Cross Hospital, Wuzhou, Guangxi, 543002 P. R. China Wuzhou Cancer Center, Wuzhou, Guangxi, 543002 P. R. ChinaSearch for more papers by this authorYonglin Cai, Yonglin Cai Wuzhou Red Cross Hospital, Wuzhou, Guangxi, 543002 P. R. China Wuzhou Cancer Center, Wuzhou, Guangxi, 543002 P. R. ChinaSearch for more papers by this authorEllen T. Chang, Ellen T. Chang Center for Health Sciences, Exponent, Inc., Menlo Park, CA, 94025, Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, 94143 USASearch for more papers by this authorZhe Zhang, Zhe Zhang Department of Otolaryngology-Head and Neck Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021 P. R. ChinaSearch for more papers by this authorGuangwu Huang, Guangwu Huang Department of Otolaryngology-Head and Neck Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021 P. R. ChinaSearch for more papers by this authorSu-Mei Cao, Su-Mei Cao State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorQing Liu, Qing Liu State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorLin Feng, Lin Feng State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorYing Sun, Ying Sun orcid.org/0000-0002-5888-2929 Department of Radiation Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorMaria Li Lung, Maria Li Lung Center for Nasopharyngeal Carcinoma Research, Research Grants Council Area of Excellence Scheme, The University of Hong Kong, Hong Kong S.A.R., 999077 P. R. China Department of Clinical Oncology, The University of Hong Kong, Hong Kong S.A.R., 999077 P. R. ChinaSearch for more papers by this authorHans-Olov Adami, Hans-Olov Adami Clinical Effectiveness Group, Institute of Health and Society, University of Oslo, Oslo, 0316 Norway Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, 17177 SwedenSearch for more papers by this authorWeimin Ye, Weimin Ye Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, 17177 Sweden Department of Epidemiology and Health Statistics & Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, Fujian, 350122 P. R. ChinaSearch for more papers by this authorTai-Hing Lam, Tai-Hing Lam School of Public Health, The University of Hong Kong, Hong Kong S.A.R., 999077 P. R. China Center for Nasopharyngeal Carcinoma Research, Research Grants Council Area of Excellence Scheme, The University of Hong Kong, Hong Kong S.A.R., 999077 P. R. ChinaSearch for more papers by this authorWei-Hua Jia, Corresponding Author Wei-Hua Jia jiawh@sysucc.org.cn orcid.org/0000-0002-0528-8715 State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. China School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, 510080 P. R. China Correspondence Wei-Hua Jia, M.D., Ph.D. Professor, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dong Feng East Road, Guangzhou 510060, Guangdong, P. R. China. Email: jiawh@sysucc.org.cnSearch for more papers by this author First published: 01 June 2022 https://doi.org/10.1002/cac2.12317 Yong-Qiao He, Wen-Qiong Xue, Dan-Hua Li, and Tong-Min Wang have contributed equally to this work. AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abbreviations EBV Epstein-Barr virus GO gene ontology GWAS genome-wide association analysis HBV hepatitis B virus HCV hepatitis C virus HLA human leukocyte antigen KEGG Kyoto encyclopedia of genes and genomes LD linkage disequilibrium NPC nasopharyngeal carcinoma PIP posterior inclusion probability QC quality control TWAS transcriptome-wide association analysis ZEBRA BamHI Z EBV replication activator Dear Editor, Nasopharyngeal carcinoma (NPC) is a common malignancy in East and Southeast Asia, especially in South China. The etiology of NPC has been linked to genetic susceptibility, Epstein-Barr virus (EBV) infection, and environmental factors. Accumulated evidence including multiple genome-wide association studies (GWASs) has revealed robust genetic predisposition of NPC. However, GWAS-identified genetic variants collectively account for only 8.2% of NPC heritability [1]. The underlying inherited predisposition is largely undetermined. The strongest genetic signal for NPC consistently hits the human leukocyte antigen (HLA) region on 6p21 [2]. However, the highly polymorphic nature and complicated long-range linkage disequilibrium (LD) in the HLA region particularly obscure the causal variants driving the association. In addition, most genetic variants located in introns or intergenic regions. The causal genes mediating genetic effects on NPC risk have rarely been ascertained by GWAS alone. Recently, transcriptome-wide association study (TWAS) has been proposed as an attractive approach to identify novel gene-trait associations and prioritize causal genes for complex traits [3]. By integrating GWAS and gene expression data, TWAS can effectively and economically assess associations between genetically predicted gene expression levels and disease risks in large populations. Hence, using the cis-regulated expression in addition to genetic variants to explore NPC susceptibility genes could be promising and reasonable for mechanistic and functional inference. Nevertheless, neither public data of nasopharyngeal tissue were available, nor TWAS for NPC had been conducted. Herein, we integrated genome and transcriptome data of 89 nasopharyngeal tumor tissues and investigated the associations between predicted gene expression levels and NPC risk using multicenter GWAS data involving 4506 NPC cases and 5384 cancer-free subjects (defined as controls) from South China. Given the close relationship between EBV infection and NPC, a cis-regulated expression weight matrix from EBV-transformed lymphocytes (n = 117) in the GTEx project was used for further evaluation. Study populations and detailed methodology are described in the Supplementary file of methods. We predicted the expression levels of 2505 and 2411 genes in the GWAS population by constructing the models for the prediction of gene expression in nasopharyngeal tissues (NP models) and EBV-transformed lymphocytes (lymphocyte models), respectively (Supplementary Table S1), and 377 genes overlapped (Supplementary Figure S1). Thirty-three genes were associated with NPC at a Bonferroni-corrected threshold, and all were located in the HLA region (Figure 1A). Among them, 11 of 13 previously reported genes were replicated. Our results were consistent with the studies focusing on the HLA region in South China [4, 5], where most of the reported genes available in TWAS were replicated. The predicted expression levels of ZFP57 (NP models), MICA (both models), and HLA-C (lymphocyte models) were significantly higher in cases than in controls, while the expression levels of MOG, HCG27, HLA-DQB1, HLA-H, HLA-U (NP models), HLA-F (both models), HLA-A, and HLA-DRB1 (lymphocyte models) were lower in cases than in controls. The two overlapping genes showed similar associations with NPC (HLA-F: Z score = -10.28 and -8.95; MICA: Z score = 7.82 and 6.60, for NP and lymphocyte models, respectively) (Supplementary Table S2). Interestingly, half of the previously reported genes belonged to HLA class I. Most of them showed lower levels of predicted expression in cases than in controls, possibly because EBV transcripts in NPC tumors were involved in the inhibition of HLA class I gene expression [6]. It is rational to assume that the low expression levels of these genes may affect the anti-EBV immune response in presenting peptides to cytotoxic T cells, facilitating immune evasion of tumor cells or EBV-mediated oncogenic action. FIGURE 1Open in figure viewer TWAS-identified susceptibility genes and pathways for NPC. (A) Manhattan plot of TWAS in NP models and lymphocyte models. The blue lines represent the Bonferroni-corrected significance threshold. The red dots above or below the blue line represent the genes passed the Bonferroni threshold in the association analysis. The genes with green labels have been reported to be associated with NPC by previous genome-wide or candidate pathway association studies. The genes with black labels were newly identified as NPC susceptibility genes by our study. The genes in different chromosomes were exhibited in light and dark grey dots. (B) Expression quantitative trait locus analysis for the seven putative causal genes in the expression data of 89 nasopharyngeal tissue samples. The Kruskal-Wallis test was used to compare medians among three genotypes for most of the variants. In a certain homozygote group, the P values were recalculated using only the wild-type and heterozygous groups for the expression of MICD, HCG27 and HLA-DOB by excluding the groups with a sample size less than 5. (C) GO pathway enrichment analysis of NPC. (D) KEGG pathway enrichment analysis of NPC. “Gene Ratio” refers to the percentage of total significant genes in the given pathway. All 354 significant genes (P < 0.05) in TWAS were used in the enrichment analysis. Abbreviations: TWAS, Transcriptome-wide association analysis; NPC, Nasopharyngeal carcinoma; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes Although the significant signals consistently hit the HLA region, 22 additional genes not previously reported were identified in TWAS. Among them, the predicted expression levels of 9 genes were significantly higher in NPC cases than in controls, including HLA-DOB, HCG4B, RPL23AP1, HLA-J in NP models and HCG4, CCHCR1, STK19, C4B, IFITM4P in lymphocyte models, while 13 other genes showed significantly lower expression levels in cases than in controls, including HCP5, ZSCAN23, HCG4P11, HCG4P7, MICD, MICB-DT, SNHG32 in NP models and NOTCH4, C4A, HCG22, POU5F1, MICE, HLA-S in lymphocyte models (Figure 1A). We performed conditional analyses to determine whether the associations between predicted gene expression levels and NPC were influenced by the GWAS signals. After conditioning on the respective GWAS index SNP, the associations for HLA-DOB, NOTCH4, ZSCAN23, STK19, C4B, HLA-J, HLA-S, and MICB-DT remained significant. After conditioning on all previously reported SNPs, NOTCH4, HCG4, HCG22, POU5F1, HCG4B, HCG4P11, MICB-DT, STK19 and IFITM4P remained significant. It indicated that their associations were partially independent of the GWAS signals (Supplementary Table S3). Due to the complicated structure with high LD and co-expression networks in the HLA region, we conducted fine-mapping analyses to prioritize the causal genes. Using posterior inclusion probability (PIP) analysis, we prioritized 7 causal genes: MICA, HLA-DQB1, HLA-DOB, ZSCAN23, HCG27, MICD, and HLA-U. HLA-DOB, ZSCAN23, and MICD were newly identified as NPC susceptibility genes (Supplementary Table S4). Furthermore, we conducted expression quantitative trait locus (eQTL) analyses to identify whether the genetic variants could influence the expression levels of these genes. We found that individuals with relevant risk SNPs (the GWAS index SNPs) exhibited higher expression of HLA-DQB1, MICA, MICD and HLA-U, or lower expression levels of ZSCAN23, HCG27, and HLA-DOB. These results indicated that the risk alleles affected the expression levels of the causal genes (Figure 1B). Two HLA class II genes (HLA-DQB1 and HLA-DOB) were prioritized as causal genes. Both genes were associated with other virus-associated cancers, such as cervical cancer [7]. A comprehensive TWAS exploring genetic susceptibility for antiviral immune response using 7924 subjects from the UK Biobank cohort revealed that the genetic determinants for EBV infection were predominantly located on HLA class II genes. The most significant signals associated with the antibody level of BamHI Z EBV replication activator (ZEBRA) hit HLA-DQB1 [8]. HLA-DOB may impact viral clearance capacity and persistent infection of hepatitis B virus (HBV) and hepatitis C virus (HCV) [9]. Since EBV reactivation with elevated EBV DNA load or antibodies was observed at the preclinical phase of NPC, we hypothesized that HLA class II genes, especially HLA-DQB1and HLA-DOB, participate in the early stage of NPC tumorigenesis by influencing EBV infection. Besides, some identified pseudogenes, such as IFITM4P [10], may function by regulating their parental genes. However, their biological mechanisms remain unclear, and further researches are needed. Gene Ontology (GO) enrichment analysis confirmed that TWAS-identified genes (354 genes with P < 0.05) were enriched in the pathways of cell-mediated immune response, antigen processing and presentation (Figure 1C). Similarly, the top pathways annotated with the Kyoto Encyclopedia of Genes and Genomes (KEGG) database focused on infection of herpes simplex virus type 1, human T-cell leukemia virus type 1, EBV, and autoimmune disorders such as graft-versus-host disease (Figure 1D). In summary, using a TWAS approach, we corroborated the central role of HLA genes in NPC susceptibility. Apart from HLA class I genes, we propose critical roles of HLA class II genes and other nonclassical HLA genes. Seven genes, including HLA-DQB1 and HLA-DOB, were prioritized as causal genes. Recent evidence indicated that these genes are pivotal in the metastable equilibrium between host and virus. Our findings provide additional evidence for a better understanding of the genetic etiology of NPC and clues to further advance this field. DECLARATIONS ACKNOWLEDGEMENTS We thank the staffs from Sun Yat-sen University Cancer Center biorepository. We thank all the study participants and research staff who recruited participants and collected samples in this study. This study was funded by the National Key Research and Development Program of China (2021YFC2500400), the Basic and Applied Basic Research Foundation of Guangdong Province, China (2021B1515420007), Sino-Sweden Joint Research Programme (81861138006), the Science and Technology Planning Project of Guangzhou, China (201804020094), the Special Support Program for High-level Professionals on Scientific and Technological Innovation of Guangdong Province, China (2014TX01R201), National Natural Science Foundation of China (81973131, 81903395, 81803319, 82003520), National Science Fund for Distinguished Young Scholars of China (81325018). CONFLICT OF INTEREST The authors have no potential conflicts of interest to declare. ETHICS APPROVAL AND CONSENT TO PARTICIPATE The Institutional Review Board of Sun Yat-sen University Cancer Center approved this study. Informed consent was obtained from all study participants. AUTHOR CONTRIBUTIONS WHJ and YQH devised the project and the main conceptual ideas; YQH, WQX, DHL, and TMW wrote the original draft; DHL and TMW performed the computational analyses; TMW, DWY, CMD, and WLZ contributed to implementation of data processing and analyses; DWY, CMD, YL, WLZ, RWX, LL, HD, XT, YW, TZ, XZL, PFZ, XHZ, SDZ, YZH, MT, YZ, YC and JBZ contributed to the sample preparation; TMW and WLZ contributed to the RNA-seq quantification and quality control pipeline; ETC, ZZ, GH, SMC, QL, LF, YS, MLL, HOA, WY, and THL contributed to the interpretation of the results; YQH, WQX, and TMW revised and wrote the final version of the manuscript; verified the analytical methods; WHJ supervised the project. All authors read and approved the final manuscript. AVAILABILITY OF DATA AND MATERIALS Methods and materials are available in the supplementary file. The datasets generated and used during the current study are available at Research Data Deposit (RDD) public platform (www.researchdata.org.cn) with the approval RDD number of RDDB2021406340. Supporting Information Filename Description cac212317-sup-0001-SuppMat.docx136.9 KB Supporting information Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. REFERENCES 1Dai J, Shen W, Wen W, Chang J, Wang T, Chen H, et al. Estimation of heritability for nine common cancers using data from genome-wide association studies in Chinese population. Int J Cancer. 2017; 140(2): 329– 36. Wiley Online LibraryCASPubMedWeb of Science®Google Scholar 2Bei JX, Li Y, Jia WH, Feng BJ, Zhou G, Chen LZ, et al. A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet. 2010; 42(7): 599– 603. CrossrefCASPubMedWeb of Science®Google Scholar 3Wainberg M, Sinnott-Armstrong N, Mancuso N, Barbeira AN, Knowles DA, Golan D, et al. Opportunities and challenges for transcriptome-wide association studies. Nat Genet. 2019; 51(4): 592– 9. CrossrefCASPubMedWeb of Science®Google Scholar 4Ning L, Ko JM, Yu VZ, Ng HY, Chan CK, Tao L, et al. Nasopharyngeal carcinoma MHC region deep sequencing identifies HLA and novel non-HLA TRIM31 and TRIM39 loci. Commun Biol. 2020; 3(1): 759. CrossrefCASPubMedWeb of Science®Google Scholar 5Tian W, Zhu F, Cai J, Li L, Jin H, Wang W. Multiple low-frequency and rare HLA-B allelic variants are associated with reduced risk in 1,105 nasopharyngeal carcinoma patients in Hunan province, southern China. Int J Cancer. 2020; 147(5): 1397– 1404. Wiley Online LibraryCASPubMedWeb of Science®Google Scholar 6Sengupta S, den Boon JA, Chen IH, Newton MA, Dahl DB, Chen M, et al. Genome-wide expression profiling reveals EBV-associated inhibition of MHC class I expression in nasopharyngeal carcinoma. Cancer Res. 2006; 66(16): 7999– 8006. CrossrefCASPubMedWeb of Science®Google Scholar 7Peng S, Trimble C, Wu L, Pardoll D, Roden R, Hung CF, et al. HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions. Clin Cancer Res. 2007; 13(8): 2479– 87. CrossrefCASPubMedWeb of Science®Google Scholar 8Kachuri L, Francis SS, Morrison ML, Wendt GA, Bosse Y, Cavazos TB, et al. The landscape of host genetic factors involved in immune response to common viral infections. Genome Med. 2020; 12(1): 93. CrossrefCASPubMedWeb of Science®Google Scholar 9Denzin LK, Khan AA, Virdis F, Wilks J, Kane M, Beilinson HA, et al. Neutralizing Antibody Responses to Viral Infections Are Linked to the Non-classical MHC Class II Gene H2-Ob. Immunity. 2017. 47(2): 310– 22 e7. CrossrefCASPubMedWeb of Science®Google Scholar 10Xiao M, Chen Y, Wang S, Liu S, Rai KR, Chen B, et al. LncRNA IFITM4P regulates host antiviral responses by acting as a ceRNA. J Virol. 2021;JVI0027721. CrossrefGoogle Scholar Early ViewOnline Version of Record before inclusion in an issue FiguresReferencesRelatedInformation

Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease Guidelines 2017—part 1: Definition, Risk Factors and Assessment

The Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease Guidelines 2017—part 2: Management and Special Groups

Expert Consensus on Perioperative Medications During Endoscopic Submucosal Dissection for Gastric Lesions (2015, Suzhou, China)

Ruxolitinib Combined with Dexamethasone in Adult Patients with Newly Diagnosed Hemophagocytic Lymphohistiocytosis: A Single‐center Pilot Trial

An Optimized Integrin Α6‐targeted Peptide for Positron Emission Tomography/magnetic Resonance Imaging of Pancreatic Cancer and Its Precancerous Lesion

Withdrawal: Prospective Randomized Comparison Between Upgraded “2C3L” Versus PVI Approach for Catheter Ablation of Persistent Atrial Fibrillation: PROMPT‐AF Trial Design

Tribute to Paul M. Vanhoutte, MD, PhD (1940–2019)

Detection of Pathogens and Antimicrobial Resistance Genes Directly from Urine Samples in Patients Suspected of Urinary Tract Infection by Metagenomics Nanopore Sequencing: A Large-Scale Multi-Centre Study

Prognostic Significance of Nodular Number in Patients Undergoing Hepatectomy of Intermediate-Stage Hepatocellular Carcinoma.

RNA M 6 A Methylation Regulates Sorafenib Resistance in Liver Cancer Through FOXO 3‐mediated Autophagy

Outcomes and Toxicities of Immune Checkpoint Inhibitors in Colorectal Cancer: a Real‐world Retrospective Analysis

A Novel Autophagy Activator Ginsenoside Rh2 Enhances the Efficacy of Immunogenic Chemotherapy

Persistent Viral Activity, Cytokine Storm, and Lung Fibrosis in a Case of Severe COVID‐19

Central Blood Pressure Measurements and Antihypertensive Therapy: a Consensus Document.

Updating the MISEV Minimal Requirements for Extracellular Vesicle Studies: Building Bridges to Reproducibility

Long‐term Outcomes of Relapsed/refractory Double‐hit Lymphoma (r/r DHL) Treated with CD19/22 CAR T‐cell Cocktail Therapy

Highly Efficient Capture of Circulating Tumor Cells by Using Nanostructured Silicon Substrates with Integrated Chaotic Micromixers

The Monoamine Oxidase-B Inhibitor Selegiline Does Not Affect 18 F-Florzolotau Uptake in Patients with Progressive Supranuclear Palsy: A Longitudinal Case Series.

Reporting Assessment of Multicenter Clinical Trial Protocols: A Cross-Sectional Study

Transcriptome-wide Association Analysis Identified Candidate Susceptibility Genes for Nasopharyngeal Carcinoma.

Identifying Circulating Glioma Cells and Their Clusters As Diagnostic Markers by a Novel Detection Platform